A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage‐Derived Stem Cells
Advanced Science · 2025
DOI: 10.1002/advs.202507794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Rui Dong und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, College of High Altitude Military Medicine, Army Medical University, Chongqing, 400038, China. Hauptthemen laut MEDLINE: Stem Cell Niche, Costal Cartilage, Bone Marrow. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing International Institute for Immunology, National Natural Science Foundation of China, Special Funds of the National Natural Science Foundation of China.
Abstract (Originalsprache)
The bone marrow (BM) niche plays a critical role in maintaining hematopoietic stem cell function but is highly vulnerable to damage from chemotherapy and radiation. However, current therapeutic strategies for BM niche failure remain significantly limited. The previous study demonstrate that costal cartilage‐derived stem cells (CDSCs) exhibit substantial self‐renewal and bone‐forming capacity; however, whether and how CDSCs contribute to BM microenvironment maintenance remains unknown. In this study, the co‐transplantation of CDSCs with multipotent progenitors (MPPs) successfully rescued lethally irradiated mice. By contrast, transplantation of mesenchymal stem cells with MPPs or MPPs alone fails to rescue the mice, suggesting a potential role of CDSCs in hematopoietic reconstitution. RNA‐seq and experimental data suggest that CDSCs are involved in rejuvenating the BM niche. Mechanistically, CDSCs not only differentiate into niche components, including bone marrow stromal cells, endothelial cells, and osteoblasts, but also secrete pro‐hematopoietic cytokines, thereby rejuvenating the irradiated microenvironment. Additionally, CDSCs protect residual hematopoietic stem and progenitor cells from radiation‐induced apoptosis and DNA damage while enhancing niche repair. Finally, through synergy with cyclosporine A, CDSCs markedly enhance hematopoietic recovery in mice with aplastic anemia. Collectively, these findings establish CDSCs as a versatile platform for treating BM failure via microenvironmental restoration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathophysiology, College of High Altitude Military Medicine, Army Medical University, Chongqing, 400038, China.
- Institute of Immunology, Army Medical University, Chongqing, 400038, China.
- Chongqing International Institute for Immunology, Chongqing, 401338, China.
- School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, 400054, China.
- Department of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, 400038, China.
Förderung
- Chongqing International Institute for Immunology
- National Natural Science Foundation of China
- Special Funds of the National Natural Science Foundation of China
Zitieren
APA
Dong, R., Ling, Z., Fan, P., Li, D., Wang, J., Shi, W., Zuo, R., Chen, R., Sun, X., Xiao, L., Ran, Y., Huang, S., Tian, Y., Zhang, C., Wu, Y., Ni, B., & Zhang, Y. (2025). A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage‐Derived Stem Cells. Advanced Science. https://doi.org/10.1002/advs.202507794
Vancouver
Dong R, Ling Z, Fan P, Li D, Wang J, Shi W, et al. A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage‐Derived Stem Cells. Advanced Science. 2025. doi:10.1002/advs.202507794
BibTeX
@article{Dong2025,
author = {Dong, Rui and Ling, Zhiguo and Fan, Pengyuan and Li, Debao and Wang, Jinsong and Shi, Wenjiong and Zuo, Rui and Chen, Runfeng and Sun, Xuemin and Xiao, Lang and Ran, Yushi and Huang, Shucheng and Tian, Yi and Zhang, Chao and Wu, Yuzhang and Ni, Bing and Zhang, Yi},
title = {A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage‐Derived Stem Cells},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202507794}
}
EUVIMED